CA3025442C - Cpf-373 protide for use in treating cancer - Google Patents

Cpf-373 protide for use in treating cancer Download PDF

Info

Publication number
CA3025442C
CA3025442C CA3025442A CA3025442A CA3025442C CA 3025442 C CA3025442 C CA 3025442C CA 3025442 A CA3025442 A CA 3025442A CA 3025442 A CA3025442 A CA 3025442A CA 3025442 C CA3025442 C CA 3025442C
Authority
CA
Canada
Prior art keywords
cancer
cpf
protide
treatment
leukaemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3025442A
Other languages
English (en)
French (fr)
Other versions
CA3025442A1 (en
Inventor
Chris Pepper
Christopher Mcguigan (Deceased)
Hugh GRIFFITH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nucana PLC
Original Assignee
Nucana PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nucana PLC filed Critical Nucana PLC
Publication of CA3025442A1 publication Critical patent/CA3025442A1/en
Application granted granted Critical
Publication of CA3025442C publication Critical patent/CA3025442C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3025442A 2016-06-01 2017-05-31 Cpf-373 protide for use in treating cancer Active CA3025442C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1609600.0A GB201609600D0 (en) 2016-06-01 2016-06-01 Cancer treatments
GB1609600.0 2016-06-01
PCT/GB2017/051560 WO2017207993A1 (en) 2016-06-01 2017-05-31 Cancer treatments

Publications (2)

Publication Number Publication Date
CA3025442A1 CA3025442A1 (en) 2017-12-07
CA3025442C true CA3025442C (en) 2024-02-20

Family

ID=56410849

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3025442A Active CA3025442C (en) 2016-06-01 2017-05-31 Cpf-373 protide for use in treating cancer

Country Status (19)

Country Link
US (2) US11400107B2 (enExample)
EP (1) EP3463384A1 (enExample)
JP (2) JP7367910B2 (enExample)
KR (2) KR20190011770A (enExample)
CN (1) CN109562119A (enExample)
AU (1) AU2017273124B2 (enExample)
BR (1) BR112018074981A2 (enExample)
CA (1) CA3025442C (enExample)
CL (2) CL2018003443A1 (enExample)
EA (1) EA038030B1 (enExample)
GB (1) GB201609600D0 (enExample)
IL (1) IL263123B (enExample)
MA (1) MA45129A (enExample)
MX (1) MX2018014840A (enExample)
MY (1) MY199129A (enExample)
PH (1) PH12018502491A1 (enExample)
SG (1) SG11201810196RA (enExample)
WO (1) WO2017207993A1 (enExample)
ZA (1) ZA201807811B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3447061T3 (da) 2011-03-01 2022-01-03 NuCana plc Farmaceutisk formulering omfattende et phosphoramidatderivat af 5-fluor-2'-deoxyuridin til anvendelse i cancerbehandling
CN111909231B (zh) 2014-11-28 2025-10-17 努卡那有限公司 作为抗癌化合物的新的2’和/或5’-氨基酸酯氨基磷酸酯3’-脱氧腺苷衍生物
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
AU2019360210B2 (en) * 2018-10-17 2025-07-10 Xibin Liao 6-Mercaptopurine nucleoside analogues
JP2020164521A (ja) * 2019-03-29 2020-10-08 国立大学法人 長崎大学 抗ウィルス薬
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
AU2021224588B2 (en) 2020-02-18 2024-07-18 Gilead Sciences, Inc. Antiviral compounds
JP7688152B2 (ja) 2021-04-16 2025-06-03 ギリアード サイエンシーズ， インコーポレイテッド アミドを使用してカルバヌクレオシドを調製する方法
JP7719954B2 (ja) 2021-08-18 2025-08-06 ギリアード サイエンシーズ， インコーポレイテッド リン脂質化合物並びにその製造方法及び使用方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
WO2007056596A2 (en) 2005-11-09 2007-05-18 Wayne State University Phosphoramidate derivatives of fau
CN104586832B (zh) 2007-09-10 2018-02-16 北京强新生物科技有限公司 用于癌症治疗的组合物和方法
EP2274617A4 (en) 2008-04-10 2011-11-09 Massachusetts Inst Technology METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
DK3447061T3 (da) 2011-03-01 2022-01-03 NuCana plc Farmaceutisk formulering omfattende et phosphoramidatderivat af 5-fluor-2'-deoxyuridin til anvendelse i cancerbehandling
AU2015265607A1 (en) 2014-05-28 2016-11-17 Idenix Pharmaceuticals Llc Nucleoside derivatives for the treatment of cancer
KR102563040B1 (ko) * 2014-06-25 2023-08-02 뉴카나 피엘씨 젬시타빈 전구 약물
PT3119794T (pt) * 2014-06-25 2018-01-15 Nucana Biomed Ltd Formulação que compreende um pró-fármaco de gemcitabina
CN111909231B (zh) * 2014-11-28 2025-10-17 努卡那有限公司 作为抗癌化合物的新的2’和/或5’-氨基酸酯氨基磷酸酯3’-脱氧腺苷衍生物
KR20180021697A (ko) * 2015-05-14 2018-03-05 뉴카나 피엘씨 암 치료
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis

Also Published As

Publication number Publication date
MX2018014840A (es) 2019-03-14
MY199129A (en) 2023-10-17
MA45129A (fr) 2021-05-05
KR20220142538A (ko) 2022-10-21
SG11201810196RA (en) 2018-12-28
AU2017273124B2 (en) 2022-09-29
JP7367910B2 (ja) 2023-10-24
CL2021002669A1 (es) 2022-05-27
US20190374564A1 (en) 2019-12-12
GB201609600D0 (en) 2016-07-13
CL2018003443A1 (es) 2019-08-09
US11400107B2 (en) 2022-08-02
PH12018502491A1 (en) 2019-09-09
KR20190011770A (ko) 2019-02-07
JP2022051965A (ja) 2022-04-01
JP2019521971A (ja) 2019-08-08
AU2017273124A1 (en) 2018-12-13
EP3463384A1 (en) 2019-04-10
ZA201807811B (en) 2024-05-30
WO2017207993A1 (en) 2017-12-07
EA201892803A1 (ru) 2019-06-28
EA038030B1 (ru) 2021-06-25
IL263123B (en) 2022-09-01
US20230218655A1 (en) 2023-07-13
IL263123A (en) 2018-12-31
BR112018074981A2 (pt) 2019-03-12
CA3025442A1 (en) 2017-12-07
CN109562119A (zh) 2019-04-02

Similar Documents

Publication Publication Date Title
US20230218655A1 (en) Cancer treatments
US20230226092A1 (en) Cancer treatments based on gemcitabine prodrugs
Sanfilippo et al. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers
AU2014312130A1 (en) Combination therapy for the treatment of glioblastoma
Shin et al. Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer
CN105611934A (zh) 用于治疗化学敏感性或化学耐药性肿瘤的Dendrogenin A和抗肿瘤剂
HK1261423A1 (en) Cancer treatments
HK1237283A1 (en) Cancer treatments
HK1237283B (en) Cancer treatments
JP6810763B2 (ja) がん治療
EA040796B1 (ru) Лечение рака

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220406

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250922

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251010

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251010

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260113